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Background. We investigated the eﬀect of laparoscopic sleeve gastrectomy (LSG) on morbidly obese diabetics and examined the
short-term impact of LSG on diabetic medication cost. Methods. A prospective database of consecutive bariatric patients was
reviewed. Morbidly obese patients with type 2 diabetes who underwent LSG were included in the study. Age, gender, body mass
index (BMI), diabetic medication use, glucose, insulin, and HbA1c levels were documented preoperatively, and at 2 weeks, 2
months, 6 months, and 12 months postoperatively. Insulin resistance was estimated using the homeostatic model assessment
(HOMA). Use and cost of diabetic medications were followed. Results. Of 178 patients, 22 were diabetics who underwent LSG.
Diabetes remission was observed in 62% of patients within 2 months and in 75% of patients within 12 months. HOMA-IR
improved after only two weeks following surgery (16.5 versus 6.6, P<0.001). Average number of diabetic medications decreased
from 2.2 to <1, within 2 weeks after surgery; corresponding to a diabetes medication cost savings of 80%, 91%, 99%, and 99.7%
after 2 weeks, 2 months, 6 months, and 12 months, respectively. Conclusion. Morbidly obese patients with diabetes who undergo
LSG have high rates of diabetes remission early after surgery. This translates to a signiﬁcant medication cost savings.
1.Introduction
The problem of obesity in the United States has reached
epidemic proportions. Over the past several decades, the
prevalence of obesity has doubled, and it is now estimated
that 20–30% of American adults are obese, and nearly two-
thirds are either overweight or obese [1, 2]. Obesity-related
comorbid conditions include type 2 diabetes, hypertension,
and obstructive sleep apnea syndrome, which account for
signiﬁcant morbidity and mortality. The coexistence of
obesity and diabetes increases the risk of cardiac disease and
death [3]. Bariatric surgery has emerged as the most eﬀective
and durable method for weight loss in the morbidly obese,
deﬁned as a BMI > 40kg/m2 or BMI > 35kg/m2 with
obesity-associated comorbid conditions [4]. In addition,
certain bariatric procedures are associated with a signiﬁcant
improvement, and even remission, of comorbidities. The
Roux-en-Y gastric bypass (RYGB) and the biliopancreatic
diversion (BPD) have been shown to provide signiﬁcant
long-term improvement or remission of type 2 diabetes
in the morbidly obese population [5, 6]. The laparoscopic
sleeve gastrectomy (LSG), ﬁrst described as a modiﬁcation of
the BPD, is emerging as a popular single-stage operation for
the treatment of morbid obesity, with acceptable morbidity
and long-term weight loss compared to the RYBG and
adjustable gastric band (AGB) [7–9]. The advantages of this
procedure include lack of an intestinal bypass, thus avoiding
metabolic derangements and internal hernias, shorter oper-
ating times, and no implantation of a foreign body [10].
In addition to weight loss, studies have suggested a positive
eﬀect of LSG on diabetes as well [3, 11, 12].
The costs of obesity and its related conditions were esti-
matedtobe$147billionin2008,andtheynowcorrespondto
more than 9.1% of annual USA medical expenditures com-
paredto6.5%in1998.Medicationcosts,meanwhile,account
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diseases [13, 14]. In this study, we investigated the early
postoperative eﬀect of LSG in morbidly obese diabetics and
examined the short-term impact of the operation on the
diabetic medication costs in these patients.
2. Methods
A prospective database of consecutive patients was reviewed
after obtaining institutional review board approval. Mor-
bidly obese patients with type 2 diabetes who underwent
LSG as a primary bariatric procedure were included in
the study. All patients carried a diagnosis of diabetes in
the medical record, were on diabetic medications, had an
abnormal fasting glucose, and had an elevated hemoglobin
A1c (HbA1c) (greater than 6.2% in our institution). All
patients met the National Institutes of Health guidelines
[14] for bariatric surgery and had a BMI greater than
35kg/m2. Each patient underwent an extensive, multidisci-
plinary preoperative workup prior to LSG. All operations
were performed by a single surgeon at the Palo Alto
VA hospital, and patients were followed by a multidis-
ciplinary team in the postoperative period. Age, gender,
BMI, diabetic medication use, fasting glucose, insulin, and
HbA1c levels were documented. Insulin resistance was esti-
mated using the calculated Homeostatic Model Assessment
(HOMA).
Use and cost of diabetic medications were followed
throughout the postoperative course. The cost of medica-
tions to treat diabetes was calculated before and after sleeve
gastrectomy, based on the current VA pharmacy-subsidized
cost for each medication. Patient data was obtained preoper-
atively and at regular intervals in the postoperative periods:
at 2 weeks, 2 months, 6 months, and 12 months after
LSG. Remission of diabetes was deﬁned as discontinuation
of diabetic medications, concurrent with normalization of
fasting glucose and HbA1c.
2.1. Surgical Procedure. A l lo p e r a t i o n sw e r ep e r f o r m e d
laparoscopically under general anesthesia, with the patient in
supine position. We used a 5-port technique with the table in
reverse-Trendelenburg position. The division of the vascular
supply to the greater curvature of the stomach was begun
6-cm proximal to the pylorus and continued to the angle
of His using the Ligasure device (Covidien, Norwalk, CT).
The sleeve gastrectomy was performed using an Echelon
Flex stapler (Ethicon, Somerville, NJ). The green staple load
(4.1/60mm) was used for the ﬁrst 3 staple ﬁrings, followed
by gold staple loads (3.8/60mm) to complete the sleeve.
Bovine pericardial Peristrips (Synovis, Surgical Innovations,
St. Paul, MN) were used to buttress the staple line in
the ﬁrst 13 operations; SeamGuard (W.L. Gore, Flagstaﬀ,
AZ) buttressing strips were used in the subsequent cases.
The sleeve volume was calibrated to an intraluminal 36 Fr
endoscope. The proximal resection line was performed 1-
2cm lateral to the angle of His to complete the sleeve. An
endoscopic airleak test was routinely used at the conclusion
oftheoperationtoconﬁrmanintactstapleline,andanupper
gastrointestinal contrast study was performed on the ﬁrst
postoperative day before introduction of oral liquid diet.
Table 1: Patient demographic data.
Preoperative morbidly
obese diabetic patients
N 22
% male/female 79/21
Mean age 55.3 years
Mean initial BMI 46kg/m2
Mean initial HbA1c 7.4%
Taking >1 diabetes med 77%
Using injectable insulin 55%
Avg. number of obesity co-morbidities
(other than diabetes) 2.9
2.2. Statistical Analysis. Comparisons of means were per-
formed using a Student’s t-test, and P<0.05 was considered
statistically signiﬁcant.
3. Results
Of178patientsinourbariatricsurgerydatabase,22weredia-
beticswhounderwentLSG.Themajorityofthepatientswere
male, with a mean age of 55.3 years and a mean preoperative
BMI of 46kg/m2 (Table 1). The average preoperative HbA1c
level was 7.4%, all patients were taking at least 1 medication
to treat diabetes, and 77% were taking more than one (mean
of 2.2 medications). Injectable insulin was used by 55% of
thepatientsbeforesurgery.Inadditiontotype2diabetes,the
patients had an average of 2.9 additional obesity-related co-
morbid conditions, including hypertension, hyperlipidemia,
obstructive sleep apnea, and osteoarthritis.
The mean duration of followup after surgery was 7
months, and the average percent excess weight loss (EWL)
in each time interval was 20% at 2 weeks postoperatively,
31% at 2 months, 47% at 6 months, and 56% at 12 months
(Figure 1). This was not signiﬁcantly diﬀerent from our
predominantly male, nondiabetic patients who underwent
LSG (56% versus 60%, P = 0.33).
The number of diabetic medications decreased from a
mean of 2.2 before surgery to less than one medication at
2w e e k sa f t e rs u r g e r y( P<0.001). This trend continued
throughoutthepostoperativeperiodthrough12months(2.2
versus 0.25, P<0.001) (Figure 2). The decrease in medica-
tion use corresponded to an improvement or remission of
diabetes (as demonstrated by normalization of fasting glu-
cose and HbA1c over the same time interval). Overall, mean
HbA1c decreased from 7.4% preoperatively to 6.1% after 12
months postoperatively (P<0.05) (Figure 3).Insulin resis-
tance, as estimated by the calculated HOMA, showed dra-
dramatic matic improvement even after only two weeks
followingsurgery(16.5versus6.6,P<0.001)(Table 2);itde-
creased by 80% after 12 months. Overall, 100% of the
patients had improvement of diabetes, and 75% had com-
plete remission at 12 months. Of those with complete remis-
sionafter1year,61%ofthepatientsdiscontinuedalldiabetic
medications within 2 weeks, and 83% were oﬀ all diabetic
medications within 2 months after surgery. Seventy-ﬁveJournal of Obesity 3
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Figure 1: Postoperative percent excess weight loss. %EWL: percent
excess weight loss.
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Figure 2: Reduction in the mean number of diabetic medications
being taken.
percent remained oﬀ diabetic medicatios at 1 year. Of the
25% still taking diabetic medications, half were on insulin,
and all of them had decreased dose requirements compared
to preoperative doses.
The cost of medications to treat diabetes was calculated
before and after sleeve gastrectomy, based on the current VA
pharmacy-subsidized cost for each medication. Decreased
use of medications corresponded to a progressive decrease
in diabetic medication costs throughout the postoperative
period. After 2 weeks, individual diabetic medication costs
decreased by 80% compared to preoperative costs. This
further decreased by 91% after 2 months and 99% after 6
months. This trend continued with >99% diabetic medica-
tion cost savings after 12 months (P<0.001) (Table 3).
Postoperative complications included a delayed presen-
tation (8 months after surgery) of a distal staple line leak
in 1 patient, postoperative nausea beyond the ﬁrst 24 hours
that resolved within 48 hours in 3 patients, and intractable
hiccups for 72 hours after surgery in 1 patient.
4. Discussion
The prevalence of obesity has been increasing worldwide,
along with a concurrent increase in morbidity due to
2weeks 2months 6months 12months
Glucose
145mg/dL
HOMA-IR 16.5
HOMA-IR 3.3
Glucose
116mg/dL
A1c 7.4%
A1c 6.1%
Preop
Figure 3: Mean change in diabetes markers. HbA1c: Hemoglobin
A1c, HOMA-IR: Homeostatic Model Assessment for Insulin Resis-
tance, and Glucose: Fasting glucose.
Table 2: Postoperative changes in markers of diabetes and insulin
resistance. HbA1c: Hemoglobin A1c, HOMA-IR: Homeostatic
Model Assessment for Insulin Resistance.
2
weeks
2
months
6
months
12
months Total
Δ HbA1c (%) − 0.6 − 0.4 0 − 0.3 − 1.3
Δ Fasting glucose
(mg/dL)
− 19.0 +5.0 − 5.5 − 9.0 −28.5
Δ fasting insulin
(mU/L)
− 24.0 − 5.1 − 1.7 −3.4 − 34.2
Δ HOMA-IR − 9.9 − 1.7 − 0.5 − 1.1 − 13.2
Table 3: Postoperative diabetic medication cost savings.
Preoperative 2
weeks
2
months
6
months
12
months
$/day 6.00 1.19 0.53 0.03 0.02
% change — − 80% − 91% −99% −99.7%
obesity-related co-morbid conditions, including type 2 dia-
betes [15]. This has been shown to result in a signiﬁcant
increase in healthcare costs [16]. The surgical treatment of
morbid obesity is known to produce signiﬁcant and durable
weight loss, along with improvement in its comorbidities
[17]. More recently, the laparoscopic sleeve gastrectomy has
emerged as a stand-alone procedure for the treatment of
morbid obesity, and unlike the Roux-en-Y gastricbypass, the
LSG does not bypass the foregut [18, 19].
Percent excess weight loss following LSG varies from 33
to 90% up to four years after surgery [10, 18]. In this study,
we report %EWL of 56% at 12 months, which is within the
lower half of this range. It is possible that total weight loss in
older males is more modest than in the general population.
In addition, it is also likely that diabetics experience lesser
weight loss after bariatric surgery compared to nondiabetics
[20]. Dietary, behavioral, and medication treatments for
obesity are often unsuccessful, and higher failure rates in4 Journal of Obesity
diabetics are associated with the use of antidiabetic agents
[21, 22].
Fewer than half of all patients with type 2 diabetes
achieve American Diabetes Association recommendations
for HbA1c [23]. Meanwhile, signiﬁcant improvement or
remission of diabetic markers is commonly observed after
bariatric surgery [3, 17, 24]. Improvement of comorbid
conditions was observed after LSG. Vidal et al. reported a
remission of type 2 diabetes after LSG in 51% of patients
after 4 months and 84% after 12 months [25, 26]. A recent
3-year study of diabetic patients after LSG demonstrated
an improvement in all comorbidities in 70% of patients
[21]. Our results are consistent with these ﬁndings, and
further suggest that the improvements in diabetes occur
early in the postoperative course. Together with the results
of Todkar et al., it additionally appears that while these
changes occur early, they are also durable [21]. Our results
are also compared favorably with a recent review of 27
studies of sleeve gastrectomy that found a 66% resolution
of diabetes with a mean followup of 13 months [3]. We
found improvement of diabetes in all our patients and
discontinuation of diabetic medications in the large majority
of patients, already within 2 months after surgery.
The mechanism responsible for remission of type 2
diabetesafterLSGhasnotyetbeenelucidatedandnecessarily
excludes the bypass of the foregut theory, as has been
suggested for the gastric bypass [27]. As has been reported by
others andsupported by the results inthis study, a signiﬁcant
reduction in diabetes markers and diabetic medications
precedes maximal weight loss [28]. In fact, we found that
signiﬁcant improvements are seen 2 weeks after surgery, and
the majority of improvements occur within two months and
are largely sustained throughout the 12 month postoperative
period. Without foregut bypass, attention has focused on
gastrichormones,includingghrelinandpeptideYY.Ghrelin,
an orexigenic hormone largely produced in the resected
gastric fundus, has been found to be signiﬁcantly reduced
after LSG compared to gastric bypass [29]. Further studies
are needed to better deﬁne the eﬀect of gastric hormone
reduction on pancreatic endocrine function and systemic
insulin resistance. In addition, it is possible that the LSG
changes the milieu of other gut hormones, producing a
positive metabolic eﬀect.
The national cost of obesity is high. Recent reports
suggest that the individual annual cost of obesity is $8,365
and $6,518 for women and men, respectively. These costs
are 15 times higher for an obese individual, compared to a
person with BMI < 30 [30]. Furthermore, medication costs
account for as much as 30% of the total cost of treating
obesity-related diseases [13, 14]. Our study results suggest
that an improvement in diabetes in the early postoperative
period translates into a signiﬁcant medication costs savings,
that is sustained for 12 months after laparoscopic sleeve
gastrectomy. Over a large population, this may translate
to a signiﬁcant impact on total healthcare expenditures.
Future studies to include costs of clinic visits and the
treatment of diabetes complications may suggest an even
greater economic impact of bariatric surgery in general and
the LSG speciﬁcally.
5. Conclusion
The laparoscopic sleeve gastrectomy produces signiﬁcant
weight loss and remission of type 2 diabetes in the earlypost-
operative period. This translates to a signiﬁcant medication
cost savings.
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